Finally, AMG PERK 44 did not enhance idarubicin efficacy and caused no major off-target effects. These findings highlight the context-dependent role of PERK in the HCC microenvironment and its implications for targeting UPR pathways in liver cancer. Impact statement This study provides an evaluation of PERK as a therapeutic target in hepatocellular carcinoma by demonstrating that its inhibition does not produce the anticipated anti-tumor effects in advanced disease, but instead exerts nuanced, context-dependent influences on the tumor microenvironment.

1 day ago

Journal

ER (Estrogen receptor) • TGFB1 (Transforming Growth Factor Beta 1) • MAPK4 (Mitogen-Activated Protein Kinase 4) • PERK (Pancreatic EIF2-Alpha Kinase) • CTGF (Connective tissue growth factor) • EIF2AK3 (Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3)

idarubicin hydrochloride

NCI-2023-03572: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms (clinicaltrials.gov)

P1, N=30, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2029 | Trial primary completion date: Dec 2026 --> May 2026

9 days ago

Enrollment closed • Trial completion date • Trial primary completion date

IL3RA (Interleukin 3 Receptor Subunit Alpha)

Chr t(15;17)

cytarabine • idarubicin hydrochloride • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)

10d

Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial. (PubMed, Blood Cancer Discov)

Fludarabine, cytarabine, and G-CSF-based therapy (FLAG) yields approximately 60% 5-year overall survival (OS) in core-binding factor (CBF) AML, with potential added benefit with gemtuzumab ozogamicin (GO)...We interrogated these factors in 219 frontline patients with CBF-AML (median age 52 years; range 19-80) treated on a phase 2 trial (NCT00801489); 51% received FLAG-GO and 49% FLAG-idarubicin...On multivariate analysis, baseline mutations did not affect OPR or survival, while FLAG-GO favored both. In CBF-AML, FLAG-based therapy possibly attenuates the prognostic impact of concurrent baseline genomics.

10 days ago

P2 data • Journal

DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)

cytarabine • Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • fludarabine IV

14d

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML (clinicaltrials.gov)

P3, N=106, Completed, Arog Pharmaceuticals, Inc. | Recruiting --> Completed | N=322 --> 106 | Trial completion date: Oct 2024 --> Apr 2026 | Trial primary completion date: Oct 2024 --> Apr 2026

14 days ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

FLT3 (Fms-related tyrosine kinase 3)

FLT3-ITD mutation

cytarabine • crenolanib (ARO-002) • idarubicin hydrochloride • mitoxantrone

16d

VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial (clinicaltrials.gov)

P2, N=48, Recruiting, Beijing 302 Hospital

16 days ago

New P2 trial

Venclexta (venetoclax) • cytarabine • azacitidine • idarubicin hydrochloride

17d

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)

P3, N=875, Recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | Not yet recruiting --> Recruiting | N=328 --> 875

17 days ago

Enrollment open • Enrollment change • Trial initiation date

NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)

NPM1 mutation

cytarabine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)

22d

Rapid screening of potent and mechanistically insightful repurposable anticancer drugs targeting EGFR for non-small cell lung cancer: machine learning-aided and structure-guided approach. (PubMed, Mol Divers)

Molecular docking revealed higher binding affinities for both Idarubicin (- 9.98 kcal/mol) and Larotrectinib (- 9.42 kcal/mol) compared to the reference drug Erlotinib (-8.91 kcal/mol). Additionally, they demonstrated favorable predicted cytotoxicity against NSCLC cell lines. In conclusion, our integrated bioinformatics analysis identifies idarubicin and larotrectinib as putative candidates for drug repurposing targeting EGFR in NSCLC, providing a rational foundation for future experimental validation and further preclinical and clinical investigations.

22 days ago

Journal

EGFR (Epidermal growth factor receptor)

erlotinib • Vitrakvi (larotrectinib) • idarubicin hydrochloride

23d

QuANTUM-WILD: Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (clinicaltrials.gov)

P3, N=700, Recruiting, Daiichi Sankyo | N=283 --> 700

23 days ago

Enrollment change

cytarabine • Vanflyta (quizartinib) • daunorubicin • idarubicin hydrochloride

23d

LIDA-BII: Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion (clinicaltrials.gov)

P2, N=44, Terminated, University Hospital, Montpellier | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; Enrollement rythm low, funding body decision.

23 days ago

Trial completion date • Trial termination

idarubicin hydrochloride

26d

ALFA2101: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics (clinicaltrials.gov)

P2, N=248, Recruiting, Centre Hospitalier Universitaire de Nice | Trial completion date: Oct 2027 --> Feb 2030 | Trial primary completion date: Oct 2027 --> Aug 2028

26 days ago

Trial completion date • Trial primary completion date

Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride

29d

VAG-3+7-G: VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (clinicaltrials.gov)

P3, N=300, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Jan 2026 --> Apr 2026

29 days ago

Trial initiation date

FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)

FLT3-ITD mutation • FLT3-TKD mutation

Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • daunorubicin • idarubicin hydrochloride

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (clinicaltrials.gov)

P3, N=204, Not yet recruiting, The First Affiliated Hospital of Soochow University

1 month ago

New P3 trial

Venclexta (venetoclax) • azacitidine • idarubicin hydrochloride • Duoenda (mitoxantrone liposomal)